L3VLUP
ProSign in

CTKB in the 13F filings

Cytek Biosciences Inc · CUSIP 23285D109

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022
Quarter end
30 Jun 2022
the date the book describes
Filed
15 Aug 2022
latest of these filings; the earliest 11 Aug 2022
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2022 and Q2 2022; 1 listed it in both
Shares listed
2,036,079
combined, among listed positions
Reported value
$22m
combined, at the quarter end

Managers listing CTKB in Q2 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Point72 Asset Management LP1,536,079$16m0.07%Addedn.a.15 Aug 2022 (the filing on sec.gov)
Glenview Capital Management LLC500,000$5.4m0.13%Added+444,58711 Aug 2022 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2022 to Q2 2022, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q2 2022 to 1 in Q2 2026

Tracked managers listing it, at least.

01122Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023Q4 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CTKB by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20221$597kn.a.n.a.
Q2 20222$22mn.a.n.a.
Q3 20221$463kn.a.n.a.
Q4 20221$320kn.a.n.a.
Q1 20231$747kn.a.n.a.
Q2 20231$987kn.a.n.a.
Q4 20251$464k1015
Q1 20261$380k912
Q2 20261$385k194

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CTKB and LLY →CTKB and JNJ →CTKB and VRTX →Choose a stock to compare with CTKB →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CTKB, latest filings →Back to the 13F Explorer →